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Background: Chronic kidney disease (CKD) is more prevalent in Taiwan than in most countries. This
population-based cohort study evaluated the dementia risk associated with CKD.
Methods: Using claims data of 1,000,000 insured residents covered in the universal health insurance of Taiwan, we
selected 37049 adults with CKD newly diagnosed from 2000–2006 as the CKD cohort. We also randomly selected
74098 persons free from CKD and other kidney diseases, frequency matched with age, sex and the date of CKD
diagnosed. Incidence and hazard ratios (HRs) of dementia were evaluated by the end of 2009.
Results: Subjects in the CKD cohort were more prevalent with comorbidities than those in the non-CKD cohort (p
<0.0001). The dementia incidence was higher in the CKD cohort than in the non-CKD cohort (9.30 vs. 5.55 per 1,000
person-years), with an overall HR of 1.41 (95% confidence interval (CI), 1.32-1.50), controlling for sex, age,
comorbidities and medicaitions. The risk was similar in men and women but increased sharply with age to an HR of
133 (95% CI, 68.9-256) for the elderly. However, the age-specific CKD cohort to non-CKD cohort incidence rate ratio
decreased with age, with the highest ratio of 16.0 (95% CI, 2.00-128) in the youngest group. Among comorbidities
and medications, alcoholism and taking benzodiazepines were also associated with dementia with elevated
adjusted HRs of 3.05 (95% CI 2.17-4.28) and 1.23 (95% CI 1.14-1.32), respectively.
Conclusions: Patients with CKD could have an elevated dementia risk. CKD patients with comorbidity deserve
attention to prevent dementia.
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Among all countries, the incidence of end-stage renal
disease (ESRD) (41.5 per 100,000) has been the highest
in Taiwan since 2000 [1-4]. There were more than 2 mil-
lion ESRD patients worldwide in 2010 requiring dialysis
or transplantation [5]. It is well known that patients with
diabetes mellitus and/or chronic kidney disease are at
high risk of developing ESRD [3-7]. The prevalence of
CKD has been shown to be higher in older adults in* Correspondence: fcsung@mail.cmu.edu.tw
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Dementia is a heterogeneous and multifactorial disorder,
including vascular-type dementia and Alzheimer-type de-
mentia [10]. The prevalence of dementia increases with
age, from less than 1% in people aged 65 years to more
than 25% in those aged 85 years or over [11,12]. Dementia
has been a hidden health issue in Taiwan in the elderly
population. The prevalence of the disorder in the elderly
in Taiwan increased continuously over past decades, from
4.1% in 1980, to 6.1% in 1990, to 8.6% in 2000 and to
10.2% in 2007 [13]. It is therefore important to identify
protective and risk factors for dementia to prevent this
disease at an early stage. CKD has been proposed as a
major factor of developing ESRD. It is also an independent
risk factor for cognitive impairment but with conflictingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recognized as comorbidities with higher incidence rate
among the elderly [10], Sasaki et al. further found the inci-
dence rate of dementia in Osaki area patients with CKD
was much higher than the general Japanese population
(24.0% vs. 9.0%) [14].
Recent studies in the US have also shown that
impaired kidney function is associated with the in-
creased prevalence of cognitive impairment [15,16].
Studies have identified age, hypertension and diabetes
mellitus as independent factors in the association be-
tween kidney function and impaired cognition [14-17].
However, there were limited population based cohort
studies on the association between CKD and the risk of
dementia. To fill this research gap, we conducted this
population based cohort study using claims data from
the National Health Insurance (NHI) in Taiwan to ex-
plore issues of (i) the association between CKD and de-
mentia in the aging population in Taiwan, (ii) the role of
other comorbidities in the risk of dementia, (iii) the rela-
tionship between medications and the risk of dementia.
Methods and materials
Data sources
The National Health Insurance (NHI) of Taiwan is a uni-
versal health insurance program reformed in 1995, offers
the coverage to 99% of the nation’s population of 23 mil-
lion, and approximately 97% of hospitals and clinics have
contracted with the NHI [18]. For research and adminis-
trative purposes, the National Health Research Institute,
Taiwan, has used the claims data to establish various sets
of database for public uses. This study used a longitu-
dinal dataset including one-million insured people ran-
domly selected from the whole population covered by
the NHI. This dataset contains information on all me-
dical services, such as ambulatory care claims, inpatient
claims and prescription drugs and registry beneficiaries
[18-20]. The privacy of all patients was protected by the
encryption of personal identification. Using the unique
scrambled personal identifications, we were able to link
these to obtain medical histories and demographic va-
riables. This study was exempted from full institutional
review.
Study subjects
In this study, we identified study subjects from 2000 to
2006 with newly diagnosed chronic kidney disease
(CKD) as CKD cohort and those without any CKD diag-
nosis as non-CKD cohort. Subjects in the CKD cohort
were identified using International Classification of Di-
seases 9th Revision, Clinical Modification [ICD-9-CM],
including 250.4(diabetes with renal manifestations),
274.1(gouty nephropathy), 403(hypertensive chronic kid-
ney disease)- 404(hypertensive heart and chronic kidneydisease), 440.1(disease of renal artery), 442.1(disease of
renal artery), 447.3(hyperplasia of renal artery), 581
(nephritic syndrome)-583(nephritis and nephropathy),
585(chronic renal failure)-588(disorders resulting from
impaired renal function). Inpatients with at least one
CKD diagnosis or outpatients with twice CKD service
claims were included in the CKD cohort. Patients with
codes of 283.1(hemolytic uremic syndrome), 572.4
(hepatorenal syndrome), 642.1(Hypertension secondary
to renal disease, complicating pregnancy, childbirth, and
the puerperium) and 646.2(Unspecified renal disease in
pregnancy, without mention of hypertension) were
excluded. Patients who had diagnoses of ESRD, renal
transplantation therapy or dialysis therapy were also
excluded. The first date of diagnosed CKD was the index
date for the follow-up time measure. Subjects with de-
mentia (ICD-9-CM 290.0, 290.1, 290.2, 290.3, 290.4,
294.1 and 331.0) prior to the index date or with missing
information on gender or age were also excluded from
this study.
For each CKD patient, two non-CKD subjects were
randomly selected frequency matching with gender, age
(every 5 years), index-year and index-month. The exclu-
sion criteria used to select CKD cohort were used to se-
lect non-CKD cohort. We also avoid selecting subjects
developing CKD in the non-CKD cohort, during the
follow-up period. The follow-up time in person-years
was calculated for each study subject until the occur-
rence of dementia, the end of 2009 or censored because
of deaths or withdrawal from the insurance program.
Other considered comorbidities at the baseline were
hypertension (ICD-9-CM 401–405, A-code A260 and
A269), diabetes mellitus (ICD-9-CM 250 and A-code
A181), ischemic heart disease (ICD-9-CM 410–414, A-
code A270 and A279), hyperlipidemia (ICD-9-CM 272.0,
272.1, 272.2, 272.3 and 272.4), tobacco use disorder
(ICD-9-CM 305.1), alcoholism (ICD-9-CM 291, 291.2,
291.9, 303.9, 334.4, 980.0, V11.3, V79.1 and V61.41),
morbid obesity (ICD-9-CM 278.0, 278.00, 278.01, 649.1,
783.1 and V77.8), atrial fibrillation (ICD-9-CM ), Parkin-
son's disease (ICD-9-CM 332 and A-code A221),
cerebrovascular disease (ICD-9-CM 430–438, A-code
A290-A294 and A299), major depressive disorder
(ICD-9-CM 296.2 and 296.3), and elevated C-reactive
protein screen (ICD-9-CM 790.95). The analysis of medi-
cation drugs related to dementia was performed for the
use of benzodiazepine, aspirin, other NSAIDs and COX2.
Statistical analysis
Data analysis first compared the demographic status and
comorbidites between CKD and non-CKD cohorts. The
Chi-square test was used to compare the difference in
gender, age and baseline comorbidities between the
CKD and non-CKD cohorts. Student’s t-test was used to






n % n % P value*
Sex 1.00
Women 33948 45.8 16974 45.8
Men 40150 54.2 20075 54.2
Age group (years) 1.00
20–39 10710 14.5 5355 14.5
40–64 34742 46.9 17371 46.9
≥65 28646 38.7 14323 38.7
Mean (SD) (years) 57.5 (15.8) 58.3 (16.1) <0.0001
Co-morbidities
Hypertension 23702 32.0 21731 58.7 <0.0001*
Diabetes mellitus 6367 8.59 11517 31.1 <0.0001*
Ischemic heart disease 12896 17.4 12056 32.5 <0.0001*
Hyperlipidemia 7350 9.92 9762 26.4 <0.0001*
Tobacco use disorder 138 0.19 135 0.36 <0.0001*
Alcoholism 294 0.40 335 0.90 <0.0001*
Obesity 398 0.54 401 1.08 <0.0001*
Atrial fibrillation 638 0.86 740 2.00 <0.0001*
Parkinson's disease 790 1.07 680 1.84 <0.0001*
Cerebrovascular disease 8701 11.7 7876 21.3 <0.0001*
Major depressive disorder 852 1.15 652 1.76 <0.0001*
Elevated C-reactive protein – – –
Medication
Use of benzodiazepine 37902 51.2 25284 68.2 <0.0001*
Use of aspirin 6992 9.44 5822 15.7 <0.0001*
Use of other NSAIDs 63174 85.3 34698 93.7 <0.0001*
Use of COX2 14584 19.7 10901 29.4 <0.0001*
*Chi-square test comparing patients with and without CKD.
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dementia for both cohorts, and the CKD cohort to non-
CKD cohort incidence rate ratio (IRR) and 95% confi-
dence interval (CI) were estimated by gender, age and
follow-up time (< 2 and ≥ 2 years). We estimated inci-
dence rates of dementia by comorbidity and medication,
and used Cox proportional hazards regression model to
estimate the specific hazard ratio (HR) and 95% confi-
dence intervals of dementia for the CKD cohort com-
pared to the non-CKD cohort. The Cox model was also
used to estimate age, sex, comorbidity and medication
specific crude HRs of dementia and the multivariate
adjusted HRs. All analyses were performed using SAS
software version 9.1 (SAS Institute Inc., Cary, NC), and
the statistical significance level was set at two-sided
p < 0.05.
Results
There were more men than women in both cohorts
(54.2% vs. 45.8%), with the mean age slightly greater in
the CKD cohort than the non-CKD cohort (Table 1).
Approximately 15% of subjects were young in 20–39
years of age. Subjects with CKD had a higher pre-
valence of all baseline comorbidities and medications
(p < 0.0001). Table 2 shows that the incidence of demen-
tia was higher in the CKD cohort than in the non-CKD
cohort (9.30 vs. 5.55 per 1,000 person-years), with an IRR
of 1.68 (95% CI 1.58-1.78). The incidence was slightly
higher in women than in men, increased with age. But the
age-specific relative risk was the highest for the youngest
subcohort with an IRR of 16.0 (95% CI 2.00-128.0),
and the lowest for the elderly with the IRR of 1.75
(95% CI 1.64-1.86). The IRR declined slightly after a
2-year follow-up.
Table 3 presents the comorbidity-specific incidence
rates of dementia in both cohorts and the CKD cohort
to non-CKD cohort hazard ratios after controlling for
age, sex, and medications. Most of comorbidities are
associated with increased dementia incidence, the high-
est for CKD patients with the comorbidity of Parkinson's
disease (50.9 per 1,000 person-years), followed by those
with atrial fibrillation (29.9 per 1,000 person-years), cere-
bralvascular disease (25.1 per1,000 person-years), etc.
These comorbidites were also associated with increased
dementia incidence for non-CKD subjects.
The CKD cohort had a higher risk of dementia than
the non-CKD cohort (adjusted HR 1.41, 95% CI 1.32-
1.50) in the multivariate Cox model (Table 4). There was
no significant different in the dementia risk between
men and women. The adjusted hazard of dementia was
much greater for the elderly (HR 133.0, 95% CI 68.9-
256), compared with those in 20–39 years of age. CKD
patients with the comorbidity of Parkinson's disease had
a crude HR of 6.92 (95% CI 6.13-7.82), compared withthe non-CKD cohort. The risk remained significant
(HR= 1.80, 95% CI 1.59-2.04) in the multivariate ana-
lysis. However, the HR in the multivariable model was
the highest for patients with alcoholism (HR= 3.05, 95%
CI 2.17-4.28). Some other comorbidities could also pre-
dict the elevated hazard of dementia for patients with
CKD, except for ischemic heart disease, hyperlipidemia,
obesity, atrial fibrillation and the use of aspirin and other
NSAIDs. The crude HR associated with hyperlipidemia
was significant, but became protective in the multivari-
able analysis. Taking benzodiazepines were also asso-
ciated with the dementia risk.
Discussion
This study revealed that the risk of dementia in the CKD
cohort was higher than that in the non-CKD cohort
Table 2 Incidence of dementia estimated by sex, age, and follow-up years for CKD and non-CKD cohorts
Non-CKD CKD
N Case Person-years Incidencerate† N Case Person-years Incidencerate† IRR (95% CI)
All 74098 2621 472301 5.55 37049 2013 216301 9.30 1.68 (1.58-1.78)
Sex
Women 33948 1293 222306 5.82 16974 969 102586 9.45 1.62 (1.49-1.77)
Men 40150 1328 249995 5.31 20075 1044 113795 9.17 1.73 (1.59-1.87)
Age, years
20–39 10710 1 72841 0.01 5355 8 36456 0.22 16.0 (2.00-128)
40–64 34742 262 234351 1.12 17371 298 111467 2.67 2.39 (2.03-2.82)
≥65 28646 2358 165109 14.3 14323 1707 68458 24.9 1.75 (1.64-1.86)
Follow-up time, year
< 2 74098 696 144691 4.81 37049 651 68898 9.45 1.96 (1.77-2.18)
≥ 2 70600 1925 327610 5.88 32917 1362 147483 9.23 1.55 (1.43-1.67)
† Incidence rate: per 1,000 person-years.
IRR (Incidence rate ratio): CKD vs. non-CKD (95% CI).
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variables and medical conditions. This result is compara-
ble with the findings in previous studies. Nickolas et al.
found that the mild cognitive impairment in older adults
with CKD is also a potentially modifiable risk factor for
dementia [21]. Another survey revealed that moderate to
severe CKD in stroke-free subjects was associated with
white matter hyperintensity, which is resulted from in-
flammation and endothelial dysfunction and is a risk for
dementia [22,23]. In addition, the present study supports
previous findings of the relationship between impaired
kidney function and cognitive decline [16,17,22,24-26].
Kahtri et al found that patients with kidney disease
even with mild CKD 訂 e at an elevated risk of cognitive
impairment [24].
It is important to note that a large proportion of CKD
patients were young, aged 20-39 years, accounting for
approximately 15% in the cohort. The young CKD
patients to the young non- CKD patients IRR of demen-
tia was near 9-fold greater than that for the elderly,
reflecting CKD has a strong impact for young people.
The corresponding IRR for 40-64 years was 13.6-fold
greater than the elderly. Our data also showed that the
risk of dementia declined with longer follow-up time, in-
dicating dementia may develop in earlier period of CKD.
Prevention care should be started earlier period includ-
ing younger CKD patients.
This study also found several comorbidities and medi-
cations could predict dementia. The associations between
blood pressure, diabetes and dementia and cognitive im-
pairment have received much attention in studies, but
the results are somewhat in conflict [25-32]. High
blood pressure increases the risk of dementia in the
elderly [26,30]. Xu et al. found that the risk of de-
mentia was especially high for patients with diabetesmellitus and severe systolic hypertension [30]. Our
results echo most of previous findings that hyper-
tension and diabetes are independent predictors of
dementia [32].
An earlier study has found that very old women with
myocardial infarction are 5-time more likely prone to
dementia than those without the disease [33]. The cross-
sectional analysis from the Rotterdam study showed that
the prevalence of dementia was increased with the de-
gree of peripheral arterial atherosclerotic disease.
The odds ratio for cognitive decline in those with severe
atherosclerosis was 3:0 [34]. Our study showed that
CKD patients with ischemic heart disease were 2.8-fold
(17.0 vs. 6.05 per 1000 person-years) more likely than
CKD patients without the comorbidity for the risk of
dementia. This association became insignificant in the
multivariate analysis.
Among comorbidities, alcoholism has the strongest as-
sociation with dementia in this study. Breteler found a
significant relationship between alcohol intake and the
risk of vascular disease [35]. Those with moderate al-
cohol intake may not at an increased risk of dementia
[36-38]. The congnitive impairment due to alcohol ad-
dition has been 臼 ported as alcohol dementia [29,39].
Alcoholism was less prevalent in our study population,
but it is an important risk factor of dementia.
In addition to alcoholism, hypertension and diabetes,
we also found that cerebrovascular disease, Parkinson's
disease and major depressive disorder were significant
comorbidities associated with dementia. Studies have
reported cerebrovascular disease as a major contributor
to later-life dementia [31,40-44]. Our findings reiterate
previous pathological investigations. The later epidemio-
logical studies may have raised the possibility that ce-
rebrovascular disease and dementia are two disorders
Table 3 Incidence of dementia estimated by comorbidity






rate† HR (95% CI)
Hypertension
No 995 3.01 337 3.48 1.64 (1.45-1.86)
Yes 1626 11.5 1676 14.02 1.48 (1.38-1.58)
Diabetes mellitus
No 2212 5.08 1203 7.83 1.52 (1.42-1.64)
Yes 409 11.2 810 12.9 1.42 (1.26-1.60)
Ischemic heart disease
No 1680 4.23 921 6.05 1.63 (1.50-1.76)
Yes 941 12.5 1092 17.0 1.52 (1.39-1.65)
Hyperlipidemia
No 2286 5.33 1491 9.36 1.65 (1.54-1.78)
Yes 335 7.78 522 9.14 1.43 (1.25-1.64)
Tobacco use disorder
No 2620 5.55 2007 9.30 1.60 (1.51-1.70)
Yes 1 1.81 6 11.1 6.73 (0.81-56.1)
Alcoholism
No 2608 5.54 1992 9.27 1.60 (1.50-1.69)
Yes 13 8.72 21 14.8 2.88 (1.41-5.91)
Obesity
No 2614 5.56 2001 9.34 1.60 (1.51-1.70)
Yes 7 3.13 12 5.32 2.81 (1.04-7.58)
Atrial fibrillation
No 2562 5.46 1929 9.03 1.59 (1.50-1.69)
Yes 59 19.2 84 29.9 1.67 (1.19-2.33)
Parkinson's disease
No 2482 5.30 1876 8.78 1.61 (1.51-1.71)
Yes 139 38.0 137 50.9 1.30 (1.02-1.65)
Cerebrovascular disease
No 1701 4.01 1048 5.89 1.59 (1.47-1.72)
Yea 920 19.2 965 25.1 1.41 (1.28-1.54)
Major depressive disorder
No 2546 5.44 1949 9.15 1.61 (1.51-1.71)
Yes 75 16.5 64 18.8 1.44 (1.03-2.03)
† Incidence rate: per 1,000 person-years.
HR: CKD vs. non-CKD (95% CI), adjsued for age, sex, use of benzodiazepine,
aspirin, other NSAIDs and COX2.
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depressive disorder are relatively less important than
cerebrovascular disease in the association with the de-
mentia risk [45-47].
Hyperlipidemia had a significant risk of dementia in
the univariate model but it became a protective effect
after being adjusted. In subjects without hyperlipidemia,the incidence of dementia in CKD patients is higher
than non-CKD patients (9.36 vs. 5.33 per 1,000 person-
years). However ,the incidence in CKD patients with
hyperlipidemia declined to 9.14 per 1,000 person-years.
The association between hyperlipidemia and dementia is
not clear. The colinearity of hypertension and hyperlip-
idemia may explain the phenomenon.
The significant relation between dementia and medica-
tions of benzodiazepines agents and aspirin is another
important finding in this study. Previous studies have
reported that the long-term use of benzodiazepines
agents is responsible for moderate-to-large weighted risk
of dementia [48-52]. The aspirin use might pose an
increased risk of intracerebral hemorrhages [53]. It is
not clear whether this is the mechanism increases the
risk of dementia.Limitations
The insurance claims data provided no measures of
serum creatinine and microalbuminuria, and we were
unable to evaluate the dementia risk based on kidney
function. CKD patients at an earlier stage might not be
included in the study. This may, therefore, have resulted
in estimating the risk for patients with more severe
condition of CKD. Second, as diagnosis of CKD and de-
mentia requires long-term observation for clinical mani-
festation, the seven-year or less observation period in
this study may be insufficient to estimate the dementia
risk with the full course of natural history. The asso-
ciated risk measures may be thus underestimated.
Third, this study included conmorbidity information at
the baseline, prior to the date of establishing the study
cohorts. Comorbidities developed during the follow-up
period may vary and the estimation of dementia risk
may vary.Conclusions
This study evaluated the risk of dementia in associations
with CKD and several medical conditions and medica-
tions for the Asian population, using representative
population-based data. We have demonstrated that pa-
tients with CKD are at a significantly higher risk of de-
mentia than those without CKD. Other comorbidity may
also interact with CKD and increase further the risk of
dementia. CKD is a much more prevalent disorder in
the current study population than populations of many
other countries. Studies are needed for patients with
CKD not only for the prevention of developing end stage
renal disease, but also for preventing the progression of
dementia. The identification of comorbidities and medi-
cations may yield important prevention opportunity for
reducing dementia development. Our data suggest that
intervention should be applied to young patients as well.
Table 4 Cox model measured hazard ratios and 95%
confidence intervals of dementia associated with CKD
and covariates
Crude Adjusted†
Variable HR (95%CI) HR (95%CI)
Sex
Women 1.00 1.00
Men 0.94 (0.89-1.00) 0.97 (0.92-1.03)
Age, years
20–39 1.00 1.00
40–64 19.7 (10.2-38.0) 16.1 (8.35-31.2)
≥65 216 (112.-414) 133 (68.9-256)
CKD
No 1.00 1.00
Yes 1.68 (1.58-1.78) 1.41 (1.32-1.50)
Hypertension
No 1.00 1.00
Yes 4.10 (3.85-4.37) 1.17 (1.09-1.26)
Diabetes mellitus
No 1.00 1.00
Yes 2.14 (2.00-2.28) 1.25 (1.17-1.34)
Ischemic heart disease
No 1.00 1.00
Yes 3.11 (2.94-3.30) 1.00 (0.93-1.06)
Hyperlipidemia
No 1.00 1.00
Yes 1.35 (1.25-1.45) 0.89 (0.83-0.97)
Tobacco use disorder
No 1.00 1.00
Yes 1.00 (0.48-2.09) –
Alcoholism
No 1.00 1.00
Yes 1.78 (1.27-2.49) 3.05 (2.17-4.28)
Obesity
No 1.00 1.00
Yes 0.64 (0.41-1.00) 0.93 (0.59-1.46)
Atrial fibrillation
No 1.00 1.00
Yes 3.77 (3.19-4.45) 1.17 (0.99-1.39)
Parkinson's disease
No 1.00 1.00
Yes 6.92 (6.13-7.82) 1.80 (1.59-2.04)
Cerebrovascular disease
No 1.00 1.00
Yes 4.85 (4.57-5.14) 1.72 (1.61-1.84)
Table 4 Cox model measured hazard ratios and 95%




Yes 2.68 (2.26-3.17) 1.95 (1.64-2.31)
Use of benzodiazepine
No 1.00 1.00
Yes 2.54 (2.37-2.71) 1.23 (1.14-1.32)
Use of aspirin
No 1.00 1.00
Yes 1.85 (1.71-2.00) 1.02 (0.95-1.11)
Use of other NSAIDs
No 1.00 1.00
Yes 1.54 (1.39-1.70) 1.01 (0.91-1.12)
Use of COX2
No 1.00 1.00
Yes 2.45 (2.31-2.60) 1.09 (1.02-1.16)
† Adjusted for sex, age, CKD, hypertension, diabetes mellitus, ischemic heart
disease, hyperlipidemia, alcoholism, obesity, atrial fibrillation, Parkinson's
disease, cerebrovascular disease, major depressive disorder, use of
benzodiazepine, aspirin, other NSAIDs and COX2.
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